All In Biotech

NDA 213330 · Hikma

Labetalol Hydrochloride

Labetalol Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Aug 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Nov 9, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

79

12 Phase 3, 13 recruiting

FAERS reports

13,484

10,245 serious, 1,375 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 19, 2025.

Labetalol HCl Injection is indicated in severe hypertension, to lower blood pressure. Labetalol Hydrochloride (HCl) is a beta-adrenergic blocker. Labetalol HCl injection is indicated in severe hypertension, to lower blood pressure. ( 1 )

Mechanism: Labetalol has both competitive alpha1-adrenergic blocking and competitive beta-adrenergic blocking activity. In man, the ratio of alpha- to beta-blockade has been estimated to be approximately 1:7 following intravenous administration. Beta 2 -agonist activity has been demonstrated in animals with minimal beta 1 -agonist activity detected.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 9, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
6 products under this application
  • LABETALOL HYDROCHLORIDE · LABETALOL HYDROCHLORIDE 10MG/2ML (5MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE · LABETALOL HYDROCHLORIDE 200MG/200ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • LABETALOL HYDROCHLORIDE IN DEXTROSE · LABETALOL HYDROCHLORIDE 200MG/200ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • LABETALOL HYDROCHLORIDE · LABETALOL HYDROCHLORIDE 20MG/4ML (5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE · LABETALOL HYDROCHLORIDE 300MG/300ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE · LABETALOL HYDROCHLORIDE 100MG/100ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Labetalol" as an intervention, any sponsor and status, largest first.

All 79 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,060
  • maternal exposure during pregnancy1,001
  • foetal exposure during pregnancy976
  • hypertension767
  • premature baby752
  • off label use726
  • exposure during pregnancy672
  • chronic kidney disease646
  • acute kidney injury645
  • fatigue616
  • renal failure581
  • nausea555

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200459
2005137
200666
200742
200844
200954
201074
2011197
2012213
2013438
2014709
2015751
2016757
2017944
20181,068
20191,223
20201,144
20211,100
20221,017
2023908
2024956
2025857
2026726

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 482 on PubMed

Sponsor: Hikma · Also marketed as Labetalol Hydrochloride In Sodium Chloride, Labetalol Hydrochloride In Dextrose

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.